MX2020011537A - Esteroides neuroactivos, composiciones y uso de los mismos. - Google Patents
Esteroides neuroactivos, composiciones y uso de los mismos.Info
- Publication number
- MX2020011537A MX2020011537A MX2020011537A MX2020011537A MX2020011537A MX 2020011537 A MX2020011537 A MX 2020011537A MX 2020011537 A MX2020011537 A MX 2020011537A MX 2020011537 A MX2020011537 A MX 2020011537A MX 2020011537 A MX2020011537 A MX 2020011537A
- Authority
- MX
- Mexico
- Prior art keywords
- depression
- tremor
- compositions
- neuroactive steroids
- anxiety disorder
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- AURFZBICLPNKBZ-YZRLXODZSA-N 3alpha-hydroxy-5beta-pregnan-20-one Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-YZRLXODZSA-N 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- AURFZBICLPNKBZ-UHFFFAOYSA-N Pregnanolone Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 AURFZBICLPNKBZ-UHFFFAOYSA-N 0.000 abstract 2
- 206010044565 Tremor Diseases 0.000 abstract 2
- 201000006517 essential tremor Diseases 0.000 abstract 2
- DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 abstract 1
- PGTVWKLGGCQMBR-FLBATMFCSA-N Ganaxolone Chemical compound C([C@@H]1CC2)[C@](C)(O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 PGTVWKLGGCQMBR-FLBATMFCSA-N 0.000 abstract 1
- -1 alphadalone Chemical compound 0.000 abstract 1
- 229950007402 eltanolone Drugs 0.000 abstract 1
- 229950006567 ganaxolone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se describen en la presente métodos tratar temblor, por ejemplo, temblor esencial; depresión, por ejemplo, posparto depresión; y trastorno de ansiedad, el método comprende administrar a un sujeto humano que padece de temblor, por ejemplo, temblor esencial; depresión, por ejemplo, posparto depresión, un trastorno de ansiedad con un esteroide neuroactivo o una composición que comprende un esteroide neuroactivo (por ejemplo, pregnanolona, alopregnanolona, alfadalona, ganaxolona, o alfaxolona).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462047599P | 2014-09-08 | 2014-09-08 | |
| US201562170596P | 2015-06-03 | 2015-06-03 | |
| US201562213015P | 2015-09-01 | 2015-09-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020011537A true MX2020011537A (es) | 2020-11-24 |
Family
ID=55459478
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003037A MX2017003037A (es) | 2014-09-08 | 2015-09-08 | Esteroides neuroactivos, composiciones y usos de los mismos. |
| MX2020011537A MX2020011537A (es) | 2014-09-08 | 2017-03-08 | Esteroides neuroactivos, composiciones y uso de los mismos. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003037A MX2017003037A (es) | 2014-09-08 | 2015-09-08 | Esteroides neuroactivos, composiciones y usos de los mismos. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20170348327A1 (es) |
| EP (1) | EP3191101A4 (es) |
| JP (3) | JP6837430B2 (es) |
| KR (2) | KR102491549B1 (es) |
| CN (2) | CN117679426A (es) |
| AU (3) | AU2015315333A1 (es) |
| BR (1) | BR112017004535A2 (es) |
| CA (1) | CA2960611A1 (es) |
| CO (1) | CO2017003396A2 (es) |
| IL (2) | IL285703B2 (es) |
| JO (2) | JOP20200195A1 (es) |
| MX (2) | MX2017003037A (es) |
| PE (2) | PE20170904A1 (es) |
| PH (1) | PH12017500427A1 (es) |
| RU (2) | RU2731000C2 (es) |
| SG (2) | SG11201701815SA (es) |
| TW (3) | TW202329978A (es) |
| WO (1) | WO2016040322A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL298436B1 (en) | 2012-01-23 | 2024-03-01 | Sage Therapeutics Inc | Pharmaceutical preparations that include allopregnanolone |
| US11410755B2 (en) * | 2014-11-06 | 2022-08-09 | Ieso Digital Health Limited | Computer-based system for providing psychological therapy |
| SI3224269T1 (sl) | 2014-11-27 | 2020-10-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
| CN107427458A (zh) * | 2015-02-06 | 2017-12-01 | 马瑞纳斯制药公司 | 静脉内加奈索酮制剂及其在治疗癫痫持续状态和其他癫痫发作病症中的用途 |
| US20180311258A1 (en) * | 2015-04-10 | 2018-11-01 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| CA3001722A1 (en) | 2015-10-16 | 2017-04-20 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| RU2022102537A (ru) | 2016-03-08 | 2022-03-30 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды, их композиции и применения |
| KR102518846B1 (ko) | 2016-08-11 | 2023-04-05 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
| CN110088091A (zh) | 2016-08-23 | 2019-08-02 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体 |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| BR112019015362A2 (pt) * | 2017-02-10 | 2020-10-20 | Asarina Pharma Ab | 3-beta-hidroxi-5-alfa-pregnan-20-ona para uso em tratamento médico |
| WO2018147791A1 (en) * | 2017-02-10 | 2018-08-16 | Asarina Pharma Ab | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor |
| CN112512505A (zh) * | 2018-04-17 | 2021-03-16 | 马特恩制药股份公司 | 用于鼻内递送孕烯醇酮的组合物和方法 |
| EP3806863A1 (en) * | 2018-06-12 | 2021-04-21 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| AU2019377074A1 (en) * | 2018-11-05 | 2021-05-13 | Ovid Therapeutics Inc. | Use of gaboxadol, ganaxolone and allopregnanolone to treat movement disorders |
| CN111281877A (zh) * | 2018-11-22 | 2020-06-16 | 南京诺瑞特医药科技有限公司 | 神经活性类固醇的新制剂 |
| WO2020118142A1 (en) | 2018-12-07 | 2020-06-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of pospartum depression |
| US20220023316A1 (en) * | 2018-12-14 | 2022-01-27 | Praxis Precision Medicines, Inc. | Methods for the treatment of depression |
| WO2020252384A1 (en) * | 2019-06-14 | 2020-12-17 | Vorsanger Gary | Treatment methods utilizing oxytocin receptor agonists |
| WO2021026124A1 (en) | 2019-08-05 | 2021-02-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treatment of status epilepticus |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| MX2022006014A (es) | 2019-12-06 | 2022-06-22 | Marinus Pharmaceuticals Inc | Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa. |
| EP4103194A4 (en) * | 2020-02-12 | 2024-03-06 | Glia Llc | PROGESTERONE COMBINATIONS |
| AU2021241622A1 (en) | 2020-03-25 | 2022-10-20 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| US11337987B1 (en) | 2021-05-07 | 2022-05-24 | Lipocine Inc. | Compositions and methods for treating central nervous system disorders |
| US11969434B1 (en) | 2022-08-29 | 2024-04-30 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
| WO2024054875A2 (en) * | 2022-09-07 | 2024-03-14 | Oxeia Biopharmaceuticals, Inc. | Treatment of mild traumatic brain injury |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| CN1171114A (zh) * | 1994-11-23 | 1998-01-21 | 科斯赛斯公司 | 用于γ-氨基丁酸受体的变构调节的雄甾烷和孕甾烷组系 |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| US6316613B1 (en) | 1997-07-25 | 2001-11-13 | Beckman Coulter, Inc. | Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis |
| WO2001032170A1 (en) * | 1999-09-13 | 2001-05-10 | Swope David M | Composition and method for decreasing neurologic symptomatology |
| EP1216713A1 (en) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
| SE0104423D0 (sv) * | 2001-12-27 | 2001-12-27 | Umecrine Ab | Pregnane steroids and their use in the treatment of CNS disorders |
| JP2005519294A (ja) | 2002-01-14 | 2005-06-30 | アンセル・ヘルスケア・プロダクツ・インコーポレーテッド | 磁気検出可能ラテックス物品 |
| US20040132826A1 (en) * | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| WO2005000869A1 (en) | 2003-05-29 | 2005-01-06 | Washington University | Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids |
| EP1591455A1 (en) * | 2004-04-29 | 2005-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Essential tremor diagnostic and treatment |
| ITMI20041763A1 (it) | 2004-09-16 | 2004-12-16 | Altergon Sa | Nuove formulazioni iniettabili contenenti progesterone |
| US8604011B2 (en) * | 2004-09-27 | 2013-12-10 | The Regents Of The University Of California | Therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| US20090074677A1 (en) * | 2007-01-08 | 2009-03-19 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| WO2008157460A1 (en) | 2007-06-15 | 2008-12-24 | Cook, Kevin, M. | Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties |
| WO2010107922A1 (en) * | 2009-03-17 | 2010-09-23 | Duke University | Neuroactive steroid compositions and methods of use for lowering cholesterol |
| FR2973031B1 (fr) | 2011-03-23 | 2013-11-29 | Univ Strasbourg | Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique |
| CA3152410A1 (en) | 2011-10-14 | 2013-04-18 | Sage Therapeutics, Inc. | 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders |
| WO2013188792A2 (en) | 2012-06-15 | 2013-12-19 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| EP3957309A1 (en) * | 2012-08-21 | 2022-02-23 | Sage Therapeutics, Inc. | Preparation of a composition comprising allopregnanolone and sulfobutylether-beta-cyclodextrin |
| CA2892811A1 (en) * | 2012-11-30 | 2014-06-05 | The Regents Of The University Of California | Allopregnanolone and a sulfobutylether-b-cyclodextrin salt for the treatment of post-partum depression |
| IL310501A (en) | 2012-12-18 | 2024-03-01 | Washington University St Louis | Neuroactive steroids converted at the 19th position to the 17th position, their prodrugs, and methods of treatment using them |
| IL286794B2 (en) | 2013-04-17 | 2024-06-01 | Sage Therapeutics Inc | 19- NOR C3, 3- dimomer C21- N- pyrazole Steroids and methods of using them |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| RS60420B1 (sr) | 2013-04-17 | 2020-07-31 | Sage Therapeutics Inc | 19-nor neuroaktivni steroidi za metode lečenja |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| RU2754534C2 (ru) | 2013-07-19 | 2021-09-03 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды, композиции и их использование |
| DK3488852T3 (da) | 2013-08-23 | 2021-02-01 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelser deraf |
-
2014
- 2014-09-08 JO JOP/2020/0195A patent/JOP20200195A1/ar unknown
-
2015
- 2015-09-08 IL IL285703A patent/IL285703B2/en unknown
- 2015-09-08 CN CN202311453621.0A patent/CN117679426A/zh active Pending
- 2015-09-08 TW TW111139662A patent/TW202329978A/zh unknown
- 2015-09-08 MX MX2017003037A patent/MX2017003037A/es unknown
- 2015-09-08 PE PE2017000428A patent/PE20170904A1/es unknown
- 2015-09-08 KR KR1020177009240A patent/KR102491549B1/ko active IP Right Grant
- 2015-09-08 RU RU2017111816A patent/RU2731000C2/ru active
- 2015-09-08 EP EP15839264.7A patent/EP3191101A4/en active Pending
- 2015-09-08 TW TW109112822A patent/TWI784261B/zh active
- 2015-09-08 SG SG11201701815SA patent/SG11201701815SA/en unknown
- 2015-09-08 JP JP2017513111A patent/JP6837430B2/ja active Active
- 2015-09-08 US US15/509,656 patent/US20170348327A1/en not_active Abandoned
- 2015-09-08 AU AU2015315333A patent/AU2015315333A1/en not_active Abandoned
- 2015-09-08 SG SG10202107866YA patent/SG10202107866YA/en unknown
- 2015-09-08 BR BR112017004535-4A patent/BR112017004535A2/pt not_active Application Discontinuation
- 2015-09-08 CA CA2960611A patent/CA2960611A1/en active Pending
- 2015-09-08 WO PCT/US2015/048937 patent/WO2016040322A1/en active Application Filing
- 2015-09-08 JO JOP/2015/0218A patent/JO3667B1/ar active
- 2015-09-08 PE PE2022000301A patent/PE20221050A1/es unknown
- 2015-09-08 KR KR1020237002066A patent/KR20230015518A/ko not_active Application Discontinuation
- 2015-09-08 TW TW104129701A patent/TWI688389B/zh active
- 2015-09-08 RU RU2020127610A patent/RU2020127610A/ru unknown
- 2015-09-08 CN CN201580060650.8A patent/CN107106574A/zh active Pending
-
2017
- 2017-03-05 IL IL250942A patent/IL250942B/en unknown
- 2017-03-07 PH PH12017500427A patent/PH12017500427A1/en unknown
- 2017-03-08 MX MX2020011537A patent/MX2020011537A/es unknown
- 2017-04-07 CO CONC2017/0003396A patent/CO2017003396A2/es unknown
-
2020
- 2020-01-22 JP JP2020008365A patent/JP2020059760A/ja active Pending
- 2020-02-10 US US16/786,160 patent/US20200253985A1/en active Pending
-
2021
- 2021-04-21 AU AU2021202433A patent/AU2021202433C1/en active Active
-
2022
- 2022-06-17 JP JP2022097944A patent/JP2022113879A/ja active Pending
-
2023
- 2023-10-11 AU AU2023248120A patent/AU2023248120A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011537A (es) | Esteroides neuroactivos, composiciones y uso de los mismos. | |
| PH12018501923A1 (en) | Neuroactive steroids, compositions, and uses thereof | |
| SG11202002085YA (en) | Neuroactive steroids and their methods of use | |
| SI2986624T1 (sl) | 19-nor nevroaktivni steroidi za metode zdravljenja | |
| MX2021001659A (es) | Esteroides neuroactivos, composiciones, y usos de los mismos. | |
| EP3258939A4 (en) | Neuroactive steroids, compositions, and uses thereof | |
| EP3149018A4 (en) | Neuroactive steroids, compositions, and uses thereof | |
| NZ720949A (en) | Methods and compositions for treating aging-associated conditions | |
| EP4335505A3 (en) | Anticonvulsant activity of steroids | |
| MX2015011132A (es) | Moduladores policiclicos del receptor de estrogenos y sus usos. | |
| IL283629A (en) | Neuroactive steroids and methods of using them | |
| MX2021005489A (es) | Metodos y composiciones para la estimulacion del sistema enteroendocrino intestinal para el tratamiento de enfermedades o condiciones relacionadas con el mismo. | |
| MX2019001323A (es) | Composiciones que comprenden 3-sulfato de 5-colesteno-3, 25-diol (25hc3s), o una sal farmaceuticamente aceptable del mismo, y por lo menos un oligosacarido ciclico. | |
| EP3661485A4 (en) | PROCESS FOR THE PRODUCTION OF THERAPEUTIC EXOSOMES FROM NANOELECTROPORATION AND OTHER NON-ENDOCYTIC CELL TRANSFECTION | |
| EP3310394A4 (en) | NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE | |
| MX2016009597A (es) | Terapias para el influenzavirus a subtipo h7n9. | |
| WO2018045078A3 (en) | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING LYMPHATIC SYSTEM DISORDERS | |
| BR112018012347A2 (pt) | método para a fabricação de corrente única de uma composição espumante, composição espumante e método para tratar um indivíduo tendo, ou em risco de ter, uma condição responsiva a corticosteroides | |
| SG11202011521RA (en) | Compositions and methods for treating steroid hormone-related diseases or disorders | |
| MY179214A (en) | Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl]6alpha, 9alpha- difluoro-17alpha-(furan-2-yl)carbonyloxy-11beta-hydroxy-16alpha- methyl-3-oxoandrosta-1,4-diene-17beta-carbothioate | |
| WO2016081701A3 (en) | CDDO-Me AS A THERAPY FOR LUPUS | |
| ZA202100093B (en) | Neuroactive steroids and methods of preparation | |
| IN2014CH01890A (es) |